Comparison of ustekinumab, infliximab and combination therapy in moderately to severely active ulcerative colitis – a study protocol of a randomized, multicenter, head-to-head COMBO-UC trial
This trial aims to determine whether combining IFX and UST can achieve higher remission rates and better long-term outcomes compared to monotherapy. The results could provide crucial insights into the optimal use of biologic agents in UC treatment, potentially establishing DTT as a standard therapy. The study's design, including extensive follow-up and robust endpoint measures, will contribute to understanding the therapeutic potential and safety profile of this combination therapy.
Authors
- Adam Fabisiak
- Renata Talar‐Wojnarowska (ORCID: https://orcid.org/0000-0003-3887-2712)
- Hubert Zatorski (ORCID: https://orcid.org/0000-0002-4932-9013)
- Grażyna Rydzewska (ORCID: https://orcid.org/0000-0002-1267-7620)
- Wojciech Fendler (ORCID: https://orcid.org/0000-0002-5083-9168)
- Piotr Eder
- Katarzyna Płoszka (ORCID: https://orcid.org/0000-0002-9573-2719)
- Ewa Małecka‐Panas (ORCID: https://orcid.org/0000-0002-1825-1807)
- Katarzyna Błaziak
Institutions
- Poznan University of Medical Sciences (PL)
- Medical University of Lodz (PL)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2024-09-19
- DOI
- https://doi.org/10.3389/fmed.2024.1458998
- Citations
- 5
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 2.75
Funders
- Agencja Badań Medycznych